Can we use HER2DX to modulate treatment intensity in HER2 positive early breast cancer?

Abstract

Clinical HER2 positive (cHER2 +) breast cancer (BC) is an heterogenous disease, which represents a major challenge in the design of personalized therapeutic strategies. In recent years, a great development against HER2 targeted therapies took place, but not all patients benefit from the same regimens. In this context, it is essential to develop genomic analysis, with clinicopathological and molecular biomarkers, as HER2DX, in order to improve response, safety, and patient's quality of life. This review aims to comprehensively summarize the current evidence regarding the development, validation, and application of HER2DX score in clinical practice. Genomic development and clinical application in the identification of different cHER2 + BC populations are discussed, along as future changing strategies for escalation and de-escalation treatments.